Influenza & Other Respiratory Viruses Flashcards

1
Q

2 clinically relevant influenza viruses

A
  1. type A:
    -potentially severe illness
    -epidemics and pandemics
    -rapidly changing
  2. type B:
    -usually less severe illness
    -epidemics
    -genetically more stable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

influenza virus - structure & virulence factors

A

*negative sense, single-stranded, enveloped RNA virus belonging to the Orthomyxoviridae family
*virulence proteins:
-hemagglutinin (H1-H18)
-neuraminidase (N1-N11)
-M2 protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

hemagglutinin

A

*important virulence factor of the influenza virus
*binds to sialic acid residues on respiratory epithelial cell surface glycoproteins
*immunity can be measured by detecting levels of neutralizing antibody to hemagglutinin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

neuraminidase

A

*important virulence factor of the influenza virus
degrades the mucus barrier** of the respiratory epithelial cells
**
facilitates release of virions
after the virus has matured within host cells by cleaving sialic acid residues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

influenza A subtypes

A

*various subtypes, grouped according to variations in HA and NA
*6 HA subtypes (importantly: H1, H2, and H3) and 5 NA subtypes (importantly: N1, N2) have infected humans
*hence, H1N1 and other types of influenza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

influenza B subtypes

A

*influenza B only has one form of HA and one form of NA (so we can just call it influenza B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

antigenic drift

A

*SMALL annual drift in minor determinants of H and N proteins
*occurs through a series of mutations, substitutions, or deletions in amino acids constituting the hemagglutinin or neuraminidase surface antigens
*occurs only after a partial viral strain has become established in humans
*represents an adaptation to the development of host antibodies
*newly developed antigenic strains prevail for a period of 2-5 years, only to be replaced by the next emerging strain
*occurs in both influenza A and B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

influenza EPIDEMICS are a result of antigenic drift or antigenic shift?

A

antigenic DRIFT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

antigenic shift

A

*LARGE shifts in H or N subtypes by REASSORTMENT
*occurs when type A influenza virus with a novel hemagglutinin or neuraminidase moves into humans from OTHER HOST SPECIES

*shifts occur less frequently than drifts
*only occurs in influenza A
*more dramatic impact due to global immunologic susceptibility = PANDMEIC
*ex. influenza pandemic of 2009 was caused by genetic reassortment between human and swine influenza A viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

influenza PANDEMICS are a result of antigenic drift or antigenic shift?

A

antigenic SHIFT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

predominant strains of circulating influenzas

A

*2 strains of type A (~80%) and 2 strains of type B (~20%)
*H3N2 (type A)
*H1N1 (type A)
*B/Yamagata lineage (type B)
*B/Victoria lineage (type B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

influenza transmission

A

*highly infectious
*transmitted by respiratory droplets:
-sneezing, coughing, talking
-contact with infected surfaces, then touching mouth, eyes, nose
*period of contagiousness:
-1 day before symptoms develop
-5 to 7 days after becoming sick
*incubation period: average 2 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

diagnosis of influenza

A

*rapid molecular assay - run on nasopharyngeal swab to detect influenza virus nucleic acids (15-30 minutes)
*PCR can be performed on respiratory samples (1-8 hour turn-around time)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

influenza - clinical manifestations

A

*febrile respiratory illness: sudden onset fever, myalgias, fatigue, cough
*mostly self-limited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

risk factors for hospitalization due to influenza

A

*elderly
*children < 2 yo
*pregnant women
*persons with comorbidities (lung disease, heart disease, neurologic disease, renal disease, obesity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

influenza clinical syndromes & complications: VIRAL PNEUMONIA

A

*rapid progression of fever, cough, dyspnea, hypoxia
*acute respiratory distress syndrome (ARDS) can result
*high mortality rate
*highest risk = heart disease, pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

2 organisms important for post-influenza bacterial pneumonia

A
  1. strep pneumo
  2. staph aureus!
18
Q

influenza clinical syndromes & complications: SECONDARY BACTERIAL PNEUMONIA

A

*characterized by typical influenza, recovery, then relapse of respiratory symptoms
*fever, cough productive of purulent sputum, lobar consolidation
*more common than viral pneumonia
*highest risk: elderly, underlying lung disease
*causative organisms:
1. strep pneumo
2. staph aureus
3. group A strep

19
Q

pathogenesis of secondary bacterial pneumonia after influenza virus

A

*destroyed/damaged physical barriers of the respiratory mucosa
*immune system dysfunction (increased glucocorticoid levels)
*increased bacterial adherence (neuraminidase-mediated)

20
Q

influenza clinical syndromes & complications: MYOSITIS & RHABDOMYOLYSIS

A

*more common in children
*muscle tenderness, especially in the legs
*markedly elevated serum creatinine phosphokinase (CPK) levels

21
Q

influenza clinical syndromes & complications: CNS involvement - Guillain Barre Syndrome

A

*ascending, progressive, symmetric muscle weakness
*absent or depressed deep tendon reflexes

22
Q

influenza clinical syndromes & complications: CNS involvement - Reye syndrome

A

*rapidly progressive encephalopathy and hepatic dysfunction in children
*aspirin use is a risk factor
*peak in 1980s, less common now

23
Q

influenza clinical syndromes & complications: MYOCARDITIS & PERICARDITIS

A

*not uncommon
*many people will present in ICU with this

24
Q

important antiviral agent used for influenza

A

OSELTAMIVIR

25
oseltamivir - uses and MOA
*antiviral medication used for type A and type B influenza treatment/prevention *neuraminidase inhibitor (blocks the viral neuraminidase enzyme) *reduces symptom duration by 1-2 days *reduces the risk of hospitalization *reduces risk of pneumonia by 55% *should be prescribed within the FIRST 48 HOURS OF SYMPTOM ONSET, but still benefit for seriously ill patients *can be used for prophylaxis in conjunction with influenza vaccine
26
influenza vaccination
*quadrivalent vaccine: -contains antigens from 4 strains of influenza viruses -two influenza A strains (H3N2 & H1N1) and two influenza B strains *everyone over the age of 6 months should get vaccinated; prioritize elderly, children/adolescents, high risk comorbidity, and health-care workers *Oct-Nov is peak vaccination season *takes about 2 weeks to be fully effective
27
influenza vaccine efficacy
*efficacy 70-90%, depending on circulating strains & host population *reduces risk of respiratory illness, pneumonia, hospitalization, death *cost effective
28
adenovirus - overview
*DNA virus *10% of respiratory infections *outbreaks among children, young adults, military
29
adenovirus - clinical manifestations, diagnosis, treatment
*fever, pharyngitis *conjunctivitis *pneumonia *myocarditis *hemorrhagic cystitis *hepatitis *diagnosis: PCR *tx: supportive
30
SARS-CoV-2 - overview
*enveloped, RNA virus in the coronaviridae family *transmitted by aerosols, droplets *adapts with genetic evolution and developing mutations *disease: COVID-19
31
SARS-CoV-2 - clinical manifestations
*clinical manifestations vary with variants: -fever, chills, cough, SOB, sore throat, congestion, new loss of taste/smell, fatigue, muscle or body aches, headache, nausea, vomiting, diarrhea *severe manifestations: -respiratory failure -ARDS -septic shock -myocarditis/pericarditis -coagulopathies -CVA -MI -kidney injury/failure
32
SARS-CoV-2 - antivirals
*remdesivir (inhibits RNA polymerase) *nirmatrelvir with ritonavir (inhibits viral protease)
33
SARS-CoV-2 - binding mechanism
*receptor-binding domain (RBD) of spike protein binds to ACE2
34
SARS-CoV-2 - immune modulators
*suppress hyperinflammation due to COVID-19 (ex. corticosteroids, IL-6 inhibitors, JAK inhibitors)
35
SARS-CoV-2 - monoclonal antibodies
*mAbs block entry of SARS-CoV-2 into human cells and neutralize the virus
36
SARS-CoV-2 - mRNA vaccines
*mRNA for SARS-CoV-2 spike protein *98% effective in preventing severe disease *induces human cells to develop antibodies against the spike protein *ADEs: injection site pain, redness, swelling, fatigue, headaches, myalgias
37
SARS-CoV-2 - protein subunit (adjuvant) vaccines
*spike protein fragments *95-99% effective in preventing moderate to severe disease
38
paramyxoviruses
*enveloped, RNA viruses *RSV, parainfluenza (croup), measles, mumps
39
respiratory syncytial virus (RSV)
*enveloped, RNA virus in paramyxovirus family *clinical manifestations: upper respiratory illness (cough, fever, wheezing, apnea), bronchiolitis, pneumonia *highest risk: infants < 6 months, premature infants, age < 2 with chronic medical conditions *diagnosis: antigen or PCR *prevention: RSV vaccine, Nirsevimab
40
measles
*enveloped, RNA virus in paramyxovirus family *acute, highly contagious viral respiratory illness *clinical syndrome: **fever, malaise, 3 C's (cough, coryza, conjunctivitis), Koplik spots, maculopapular rash** *complications: otitis media, pneumonia, death, acute encephalitis, subacute sclerosing pancencephalitis *prevention: MMR vaccine (live, attenuated vaccine)